pillbase.ru

Rybrevant

Active substance: amivantamab

amivantamab

Centralised EU authorisationActive

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 1
  • Рибревант
    концентрат для приготовления раствора для инфузий, 350 мг, 7 мл (original in Russian, GRLS)
    ЛП-№(014025)-(РГ-RU)
    ООО "Джонсон & Джонсон"
US 5
  • Rybrevant
    INJECTION · AMIVANTAMAB 350 mg/1
    57894-501
    Janssen Biotech, Inc.
  • Rybrevant Faspro
    INJECTION · AMIVANTAMAB 2240 mg/14mL, HYALURONIDASE (HUMAN RECOMBINANT) 28000 mg/14mL
    57894-514
    Janssen Biotech, Inc.
  • Rybrevant Faspro
    INJECTION · AMIVANTAMAB 2400 mg/15mL, HYALURONIDASE (HUMAN RECOMBINANT) 30000 mg/15mL
    57894-515
    Janssen Biotech, Inc.
  • Rybrevant Faspro
    INJECTION · AMIVANTAMAB 3520 mg/22mL, HYALURONIDASE (HUMAN RECOMBINANT) 44000 mg/22mL
    57894-522
    Janssen Biotech, Inc.
  • Rybrevant Faspro
    INJECTION · AMIVANTAMAB 1600 mg/10mL, HYALURONIDASE (HUMAN RECOMBINANT) 20000 mg/10mL
    57894-510
    Janssen Biotech, Inc.
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-dbb9-770c-a8f2-c525bdfd6071;count=1 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208f-f65e-7be4-84d3-01dcb734e8b3;count=1 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/005454
Registration status
Active
ATC code
L01FX18
Sources
  • product · EMA · EMEA/H/C/005454 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/005454 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/005454 · Verified 2026-10-09